41% of infants with spinal muscular atrophy saw motor function improvement with new drug: 8 takeaways

Megan Wood -   Print  |

Orlando, Fla.-based Nemours Children's Hospital researchers studied the impact of a new medication nusinersen on infants with severe spinal muscular atrophy.

The study involved 121 infants with SMA Type 1. The infants either received nusinersen injections or a sham treatment.

 

New England Journal of Medicine published the study.

 

Here are eight takeaways:

 

1. Nusinersen's effects were so impressive during the study the FDA approved the medication earlier than anticipated, in 2016. The drug is available as Spinraza.

 

2. With an antisense oligonucleotide, nusinersen modifies the SMN2 gene, which is injected into the spinal fluid. The spinal cord's nerve cells then absorb the DNA to boost neuromotor development protein production.

 

3. Over 13 months, 41 percent of the nusinersen group saw improvements in motor function. Some of the infants started developing the following skills: kicking, head control, rolling over and standing.

 

4. No infants in the control group saw motor skill improvement.

 

5. The death risk proved 63 percent lower for the nusinersen group compared to the control group.

 

6. The nusinersen-treated infants were 47 percent more likely to survive without permanent assisted ventilation.

 

7. The infants treated with nusinersen mostly tolerated the drug, and researchers noted no serious safety issues associated with the drug.

 

8. Other studies, testing aspects such as the long-term effects of the drug, are now occurring.

 

More articles on spine:
Dr. Arthur Jenkins to leave academic post at Mount Sinai for independent practice in 2018: 5 key notes
1st 5 spine surgery cases with coflex in a NY ASC; 30 minimally invasive spine devices to know & more — 7 outpatient spine stories
Dr. Jared Fridley joins Comprehensive Spine Center at Rhode Island and Newport Hospitals: 5 notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers